KR20080114683A - 질병에 대한 바이오마커로서의 지방생성 아데노바이러스 - Google Patents

질병에 대한 바이오마커로서의 지방생성 아데노바이러스 Download PDF

Info

Publication number
KR20080114683A
KR20080114683A KR1020087018439A KR20087018439A KR20080114683A KR 20080114683 A KR20080114683 A KR 20080114683A KR 1020087018439 A KR1020087018439 A KR 1020087018439A KR 20087018439 A KR20087018439 A KR 20087018439A KR 20080114683 A KR20080114683 A KR 20080114683A
Authority
KR
South Korea
Prior art keywords
adenovirus
cancer
subject
adipogenic
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087018439A
Other languages
English (en)
Korean (ko)
Inventor
리차드 엘. 악킨슨
Original Assignee
오베테크, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오베테크, 엘엘씨 filed Critical 오베테크, 엘엘씨
Publication of KR20080114683A publication Critical patent/KR20080114683A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
KR1020087018439A 2005-12-27 2006-12-27 질병에 대한 바이오마커로서의 지방생성 아데노바이러스 Ceased KR20080114683A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75340205P 2005-12-27 2005-12-27
US60/753,402 2005-12-27

Publications (1)

Publication Number Publication Date
KR20080114683A true KR20080114683A (ko) 2008-12-31

Family

ID=38610014

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087018439A Ceased KR20080114683A (ko) 2005-12-27 2006-12-27 질병에 대한 바이오마커로서의 지방생성 아데노바이러스

Country Status (11)

Country Link
US (5) US7442511B2 (https=)
EP (2) EP1977009B1 (https=)
JP (1) JP2009521707A (https=)
KR (1) KR20080114683A (https=)
CN (1) CN101389768B (https=)
AU (1) AU2006342053A1 (https=)
BR (1) BRPI0620755A2 (https=)
CA (1) CA2635269A1 (https=)
MX (1) MX2008008453A (https=)
RU (1) RU2008130893A (https=)
WO (1) WO2007120362A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507418B2 (en) * 2005-09-09 2009-03-24 Obetech, Llc Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
US7442511B2 (en) * 2005-12-27 2008-10-28 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
JP2009156254A (ja) * 2007-12-05 2009-07-16 Ibiden Co Ltd 排気ガス処理体の保持シール部材及び排気ガス処理装置
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010011440A2 (en) * 2008-06-16 2010-01-28 Obetech Llc Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011050299A2 (en) * 2009-10-22 2011-04-28 Obetech Llc Adenovirus infection in animals
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2011119915A2 (en) * 2010-03-25 2011-09-29 Obetech Llc Method for detecting lipogenic adenovirus
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US8951980B2 (en) * 2010-07-08 2015-02-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus Ad36 E4 orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
WO2012006550A2 (en) * 2010-07-09 2012-01-12 Obetech Llc Methods and compositions for treatment of lipogenic virus related conditions
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
US9925254B2 (en) 2014-11-05 2018-03-27 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
JP7362667B2 (ja) 2018-02-12 2023-10-17 イニミューン・コーポレーション Ｔｏｌｌ様受容体リガンド
AU2019352906B2 (en) * 2018-10-05 2026-01-22 Minomic International Ltd. Biomarker combinations for determining aggressive prostate cancer
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
AU6884298A (en) * 1997-04-04 1998-10-30 Obetech, Llc Viral obesity methods and compositions
JP2000072800A (ja) * 1998-08-26 2000-03-07 Toagosei Co Ltd 抗アデノウイルス３７型モノクローナル抗体及びその用途
CA2632013C (en) * 2005-11-30 2013-02-26 Wayne State University Adenovirus 36 e4 orf 1 gene and protein and their uses
US7442511B2 (en) * 2005-12-27 2008-10-28 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease

Also Published As

Publication number Publication date
US7442511B2 (en) 2008-10-28
US7910310B2 (en) 2011-03-22
CN101389768A (zh) 2009-03-18
US7745110B2 (en) 2010-06-29
EP1977009A2 (en) 2008-10-08
RU2008130893A (ru) 2010-02-10
WO2007120362A3 (en) 2008-08-14
BRPI0620755A2 (pt) 2011-11-22
WO2007120362A2 (en) 2007-10-25
US20070218081A1 (en) 2007-09-20
US20090087833A1 (en) 2009-04-02
US20090087455A1 (en) 2009-04-02
US20110189235A1 (en) 2011-08-04
EP1977009B1 (en) 2016-08-17
US20130323273A1 (en) 2013-12-05
AU2006342053A1 (en) 2007-10-25
JP2009521707A (ja) 2009-06-04
CA2635269A1 (en) 2007-10-25
EP1977009A4 (en) 2009-06-03
CN101389768B (zh) 2015-11-25
EP2390372A1 (en) 2011-11-30
MX2008008453A (es) 2008-11-28

Similar Documents

Publication Publication Date Title
US7910310B2 (en) Adipogenic adenoviruses as a biomarker for disease
USRE42129E1 (en) Viral obesity methods and compositions
JP3676195B2 (ja) ヒトパピローマウイルス１８のタンパク質における血清反応性エピトープ
CN102558336B (zh) Prr11基因及其编码的蛋白和应用
US20090220946A1 (en) Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
Xu et al. KAT8 facilitates the proliferation of cancer cells through enhancing E7 function in HPV-associated cervical cancer: Role of KAT8 in HPV-associated cervical cancer
US20100144589A1 (en) Methods of predicting cancer lethality using replikin counts
CN110885366A (zh) 肝癌的肿瘤标志物热休克因子2结合蛋白及其应用
JP2002515725A (ja) カポジ肉腫および腹膜後繊維腫症に関連するガンマヘルペスウイルスのｄｎａポリメラーゼ
CN110628728A (zh) 靶向癌症的重组溶瘤基因-腺病毒及其构建方法和应用
Egg et al. The Controversial Link Between Human Papillomavirus Infection and Esophageal Health: An Exploratory Translational Study
WO2010011440A2 (en) Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
WO2010017514A2 (en) Methods of predicting cancer lethality using replikin counts
KR100785397B1 (ko) 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
CN111139299A (zh) Josd2蛋白在制备治疗恶性肿瘤药物中的应用
CN109295015B (zh) E3泛素连接酶trim7在肝癌中的应用
CN115840046A (zh) 一种鉴别anti-VEGF抗体获得性耐药的蛋白聚糖ESM1生物学标记物及其应用
CN120629571A (zh) Lepr基因或蛋白作为靶标在制备胆管细胞癌治疗产品中的用途
JP2022513152A5 (https=)
CN121177475A (zh) 维甲酸诱导蛋白16在制备防治基孔肯雅病毒感染药物中的应用
CN113322320A (zh) 一种长非编码rna及其在诊断及治疗神经胶质瘤中的应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080725

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130724

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131031

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130724

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I